Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
REGN728 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Cohort 1 | EXPERIMENTAL | Dose 1 versus placebo |
| Cohort 2 | EXPERIMENTAL | Dose 2 versus placebo |
| Name | Type | Description |
|---|---|---|
| REGN728 | BIOLOGICAL | 2 Subcutaneous Cohorts (dose 1, 2) |
Inclusion Criteria: * Male or female 18 to 65 years of age. * Weight\> 50 kg and \<95 kg inclusive * For men of childbearing potential, willingness to utilize adequate contraception and not have their partner\[s\] become pregnant during the full duration of the study. * Willing, committed, and able...
REGN728 is an investigational monoclonal antibody being developed by Regeneron Pharmaceuticals, Inc. (REGN). It is currently in Phase 1 clinical development. The drug has been studied in a completed trial involving healthy volunteers to assess its safety and tolerability.
REGN728 is being studied for use in healthy volunteers. The completed Phase 1 trial evaluated the safety and tolerability of ascending doses of REGN728 in healthy individuals. Its potential therapeutic applications have not been established, as it is still in early-stage clinical development.
REGN728 is developed by Regeneron Pharmaceuticals, Inc., a biopharmaceutical company traded on the Nasdaq under the ticker symbol REGN. Regeneron is conducting clinical research on REGN728 as an investigational monoclonal antibody.
REGN728 is in Phase 1 clinical development. A Phase 1 trial, NCT01197391, has been completed. This trial was a randomized, double-blind, controlled ascending dose study in healthy volunteers. The drug remains investigational and has not been approved by regulatory authorities.
REGN728 has one completed clinical trial, NCT01197391, titled "Ascending Dose Study of the Safety and Tolerability of REGN728 in Healthy Volunteers." This Phase 1 study enrolled 48 healthy participants in the United States and was randomized, double-blind, and controlled.